Current treatments focus on controlling inflammation and minimizing long-term damage. Learn more.

Chronic lung disease is associated with a higher risk for infection in patients with ANCA-associated vasculitis during both induction and maintenance treatment.

Almost all AAV cases were diagnosed in individuals with high pretest probability, including those with renal disease, peripheral neuropathies, or pulmonary infiltrates.

ANCA-associated vasculitis (AAV), a condition that causes inflammation in small to medium-sized blood vessels, can affect organs throughout your body. That means you will likely need more than one ...

Pulmonary involvement is highly prevalent in individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), affecting 82.7% of patients with granulomatosis with polyangiitis ...

Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...

The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.

Laura Schober is a writer and editor specializing in health, food, wellness, beauty, and lifestyle content. Laura is also a seasoned communications professional who has previously worked in the ...

Scarring, whether caused by acne, surgery or another wound-inducing experience, is almost as inevitable as it is permanent. If your scars create textural changes to your skin, medical intervention via ...